title: Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
abstract: Skeletal complications of cancer decrease health-related quality of life. Bisphosphonates can prevent skeletal-related events. We collected resource use data prospectively for 930 patients alongside a multinational trial of zoledronic acid versus pamidronate for patients with metastatic multiple myeloma or breast cancer and > or =1 bone lesion. Country-specific unit costs were assigned to counts of resource use from randomization through last trial visit. Total costs were calculated by summing costs for medical resources, plus costs of institutional care and study medications and administration. Resource use was similar for both groups. Approximately half of the patients were hospitalized at least once during the mean follow-up of 10 months (52.8% for zoledronic acid versus 52.6% for pamidronate; P = 0.9504). The average number of hospital days was 8.9 for zoledronic acid versus 9.2 for pamidronate (P = 0.728). The mean total cost was 16,434 dollars for zoledronic acid and 15,735 dollars for pamidronate, an incremental cost of 699 dollars (95% confidence interval [CI], -1047 to 2163). Mean total costs for patients with multiple myeloma were 1982 dollars (95% CI, -1491 to 5335) higher for zoledronic acid (17,958 dollars) than for pamidronate (15,976 dollars). However, among patients with breast cancer, total costs in both groups were approximately equal (15,703 dollars for zoledronic acid versus 15,680 dollars for pamidronate; 95% CI for the difference: -1875 to 2012). There were no significant cost differences between patients receiving zoledronic acid and those receiving pamidronate.
authors.affiliation: Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
authors.forename: Shelby D
authors.initials: SD
authors.lastname: Reed
authors.forename: Jasmina I
authors.initials: JI
authors.lastname: Radeva
authors.forename: G Alastair
authors.initials: GA
authors.lastname: Glendenning
authors.forename: Robert E
authors.initials: RE
authors.lastname: Coleman
authors.forename: Kevin A
authors.initials: KA
authors.lastname: Schulman
mesh_terms: D000553:Ambulatory Care / Q000191:economics; D001859:Bone Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000556:secondary*; D001943:Breast Neoplasms / Q000191:economics* / Q000473:pathology; D003365:Costs and Cost Analysis; D004164:Diphosphonates / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007093:Imidazoles / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000191:economics* / Q000473:pathology; D000077268:Pamidronate; D016032:Randomized Controlled Trials as Topic; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate